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Background: TcpB is a TIR-domain-containing 
protein form Brucella 
Results: TcpB interacts with the host Toll-like 
receptor and adaptors and its structure reveals a 
dimer essential for activity. 
Conclusions: TcpB forms a non-functional 
complex with host molecules, thus suppressing 
signaling.  
Significance: The work explains the structural 
and functional basis of immune suppression by 
the protein TcpB from a pathogenic bacterium.  
 
ABSTRACT  
Upon activation of Toll-like receptors (TLRs), 
cytoplasmic Toll/interleukin-1 receptor (TIR) 
domains of the receptors undergo homo- or 
hetero-dimerization. This in turn leads to the 
recruitment of adaptor proteins, activation of 
transcription factors, and the secretion of 
pro-inflammatory cytokines. Recent studies 
have described the TIR-domain-containing 
protein from Brucella melitensis, TcpB 
(BtpA/Btp1), to be involved in virulence and 
suppression of host innate immune responses. 
TcpB interferes with TLR4 and TLR2 
signaling pathways by a mechanism that 
remains controversial. In this study, we show 
using co-immunoprecipitation analyses that 
TcpB interacts with MAL, MyD88, and TLR4, 
but interferes only with the MAL:TLR4 
interaction. We present the crystal structure 
of the TcpB TIR domain, which reveals 
significant structural differences in the loop 
regions compared to other TIR domain 
structures. We demonstrate that TcpB forms 
a dimer in solution, and the crystal structure 
reveals the dimerization interface, which we 
validate by mutagenesis and biophysical 
studies. Our study advances the 
understanding of the molecular mechanisms 
of host immunosuppression by bacterial 
pathogens.   
 
Toll-like receptors (TLRs) are a family 
of pattern recognition receptors (PRRs) that 
sense danger in the forms of both conserved 
microbial molecules and host-derived factors 
that are present when homeostasis is 
dysregulated (1). The Toll/interleukin-1 receptor 
(TIR) domain is a key molecular component of 
TLR-mediated innate immune response 
pathways. All mammalian TLRs and several 
cytosolic adaptor proteins contain TIR domains 
in their C-terminal regions (2). Homo- or 
heterotypic dimerization of receptor TIR 
domains are required to initiate downstream 
signaling via the recruitment of TIR-domain-
containing adaptor proteins such as myeloid 
differentiation primary response gene 88 
(MyD88), TIR-domain-containing adaptor 
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protein inducing INF-β (TRIF), MyD88 adaptor-
like protein (MAL), and TRIF-related adaptor 
molecule (TRAM) (2). Recruitment of one or a 
combination of these adaptors to TLRs leads to 
the activation of transcription factors such as 
nuclear factor-κB (NF-κB), activator protein-1 
(AP-1), and interferon regulatory transcription 
factor 3 (IRF3). This enables regulated 
expression of a suite of innate-immune genes, 
including those encoding pro-inflammatory 
cytokines and chemokines that drive immune 
cell recruitment to the inflammatory lesion (1).  
Brucellosis, which results in more than 
500,000 deaths annually worldwide, is a 
zoonotic disease in humans caused by the Gram-
negative Brucella (3,4). Brucella spp. have 
developed different strategies to evade TLR-
mediated host innate immune recognition. One 
strategy involves the production of virulence 
factors that interact with and antagonize key 
signaling components to suppress TLR signaling 
(3,5). Recent studies have identified a TIR-
domain-containing protein known as TcpB, 
BtpA or Btp1 produced by Brucella melitensis 
(hereafter, we use the term TcpB) (6,7). It has 
been reported that TcpB restricts pro-
inflammatory responses by suppressing the 
TLR4-, TLR2-, MAL- and MyD88-mediated 
activation of NF-κB and inhibiting dendritic 
cells maturation (8-11). The protein contains two 
domains, an N-terminal domain reported to bind 
to phosphoinositides (10) and a C-terminal TIR 
domain (TcpB-TIR). Radhakrishnan et al. (10) 
suggested that TcpB mimics MAL by using its 
N-terminal domain to bind to lipids in the 
plasma membrane and competes with MAL for 
binding to MyD88. However, Sengupta et al. (9) 
reported that TcpB interacts with MAL and not 
MyD88, and that TcpB does not interfere with 
the MAL:MyD88 interaction. Notably, TcpB 
binding to MyD88 has been reported in other 
studies (7,11), with a recent study by Chaudhary 
et al. (12) suggesting that TcpB binds to MyD88 
with higher affinity compared to MAL. The data 
reported so far do not agree on the mechanism 
by which TcpB interacts with mammalian TIR-
domain-containing proteins (6). Although TIR 
domains generally interact homo- or 
heterotypically with other TIR domains (2), all 
previous TcpB interaction studies used full-
length TcpB. Furthermore, the interaction of 
TcpB with MyD88 was suggested to be 
independent of the MyD88 TIR domain (12).  
Although TIR domain homo- and 
heterotypic association is clearly crucial for TLR 
signaling, the majority of isolated TIR domains 
exist as monomers in solution (2). Crystal 
structures of TIR domains from mammalian, 
plant and bacterial TIR-domain-containing 
proteins have significant structural differences, 
and analyses of the crystal lattices have not 
revealed any common homotypic TIR:TIR 
domain interfaces (2,13-21). However, 
mutational studies have validated a number of 
proposed interfaces, often involving different 
loop regions (2). Although the available data 
suggest that microbial TIR-domain-containing 
proteins may also be functional as dimers (2,22), 
the mechanisms of action are not clear.  
In order to elucidate the molecular basis 
of function of the microbial TIR-domain-
containing proteins, we used the Brucella 
melitensis TcpB protein as a model to study the 
interaction between the bacterial and mammalian 
TIR-domain-containing proteins. Using co-
immunoprecipitation assays, we show that TcpB 
can interact with MAL, MyD88 and TLR4, with 
the interaction interface for both MAL and 
TLR4 involving the TcpB BB-loop. TcpB does 
not interact with TRAM or IRAK-2, suggesting 
that TcpB specifically targets the MAL-
dependent signaling pathway. Furthermore, 
competition assays demonstrate that TcpB 
disrupts the receptor:adaptor interaction between 
TLR4 and MAL, but not the adaptor:adaptor 
interaction between MAL and MyD88. We also 
show that TcpB exists as a stable dimer in 
solution and that both the TIR and N-terminal 
domains are involved in self-association. 
Structural and functional analysis of the TcpB 
TIR domain reveals a homotypic interface that is 
required for potent NF-κB suppression mediated 
by TcpB. This study provides new insights into 
the mechanism of bacterial TIR-domain-
containing protein immunomodulation of TLR 
signaling at the molecular and structural level. 
 
EXPERIMENTAL PROCEDURES 
Plasmids. For recombinant protein expression in 
Escherichia coli, the cDNA of the full-length 
TcpB (TcpB-fl) was generated by PCR-based 
gene synthesis and used for cloning TcpB-fl, the 
TcpB-TIR domain (TcpB120-250), a longer 
construct containing the TcpB-TIR domain 
(TcpB70-250) and the TcpB N-terminal domain 
(TcpB1-119) sequences into the pMCSG7 vector 
(23), and subsequent transformation into 
Escherichia coli BL21 (DE3) for protein 
expression. The TcpB residue numbering used in 
the paper corresponds to the UniProt accession 
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ID Q8YF53. For protein expression in 
mammalian cells, a plasmid encoding the cDNA 
of TcpB-fl (obtained from Thomas Miethke, 
Technical University, Munich; (11)) was used to 
clone TcpB and its mutants into the pEF6/V5 
vector (Invitrogen), to be subsequently used in 
luciferase NF-κB reporter assays and co-
immunoprecipitation studies. HA-MyD88, HA-
MAL, HA-TLR4, Flag-MAL, Flag-TRAM, 
Myc-IRAK-2, NF-κB reporter gene, and phRL-
TK reporter gene were obtained from Andrew 
Bowie (Trinity College, Dublin, Ireland).  
Immunoprecipitation and immunoblotting. 
HEK293 cells (1 x 106 cells/well) were seeded 
into 6-well plates, 24 h before transfection with 
lipofectamine 2000. Cells were harvested after 
24 h using 350 µl Ripa lysis buffer (50 mM Tris 
pH 8, 150 mM NaCl, 1 mM EDTA, 1% Triton 
X100, 0.1% SDS, 1% sodium deoxycholate). To 
test the interaction of TcpB and TcpBG158A with 
MAL, MyD88, TLR4, TRAM and IRAK-2, 1 µg 
of full-length V5-TcpB or V5-TcpBG158A was co-
transfected with 1 µg of HA-MAL, HA-MyD88, 
HA-TLR4, Flag-TRAM, Myc-IRAK-2 or HA-
tagged control protein (all correspond to full-
length proteins). 50 µl of lysate was retained for 
analysis of protein expression. The remainder 
was incubated with 2 µl anti-V5 for 2 h at 4°C 
with rotation. 25 µl of pre-washed (washing 
buffer: 10 mM Hepes pH 8.0, 1.5 mM MgCl2, 10 
mM KCl, 150 mM NaCl) Dynabeads® Protein G 
(Life Technologies) magnetic beads were added 
to the lysate and further incubated for 2 h at 4°C 
with rotation. The lysates were then washed 
three times with high-salt-concentration buffer 
(10 mM Hepes pH 8.0, 1.5 MgCl2, 10 mM KCl, 
300 mM NaCl). To test the interference of TcpB 
with receptor:adaptor or adaptor:adaptor 
interactions, 1 µg of Flag-MAL or Flag-TRAM 
was co-transfected with 1 µg of HA-MyD88 or 
HA-TLR4. The lysate was incubated with 2 µl of 
anti-Flag-M2 for 2 h at 4°C with rotation. 25 µl 
of pre-washed (washing buffer: 10 mM Hepes 
pH 8.0, 1.5 mM MgCl2, 10 mM KCl, 150 mM 
NaCl) Dynabeads® Protein G (Life 
Technologies) magnetic beads were added to the 
lysate and further incubated for 2 h at 4°C with 
rotation. Increasing amounts (1, 10, 100 µg) of 
recombinant  TcpB-fl, TcpB120-250, TcpB1-119  or 
GST proteins were added to the lysate and 
further incubated for 3 h at 4°C with rotation. 
The lysates were then washed three times with 
high-salt-concentration buffer. Samples were 
subjected to SDS-PAGE and transferred onto a 
nitrocellulose membrane for immunoblotting.  
NF-κB luciferase reporter assay. To compare 
the NF-κB suppression activity of wild-type 
versus mutant full-length TcpB, HEK293-TLR4-
MD2 cells were seeded into 24-well plates (8 x 
104 cells/well). 24 h later, cells were co-
transfected with 100 ng of NF-κB-luciferase 
reporter gene, 20 ng/well of phRL-TK reporter 
gene, and 200 ng of TcpB or TcpB mutants 
using lipofectamine 2000. The total amount of 
DNA per transfection was kept constant at 460 
ng by addition of pGL-2B empty vector (EV). 
After 24 hours, cells were stimulated with 100 
ng/ml LPS. After a further 8 hours, cells were 
lysed in Passive Lysis buffer (Promega) and 
whole cell lysates were analyzed for firefly and 
Renilla luciferase activities using Dual 
Luciferase Assay kit (Promega). Firefly 
luciferase activity was normalized to Renilla 
luciferase activity, and data are expressed as 
relative luciferase activity, and are representative 
of three independent experiments, each 
performed in duplicate. Statistical analysis was 
carried out in GraphPad Prism version 6 (San 
Diego, California, USA) using two-way 
ANOVA with Dunnett’s multiple comparisons 
test.  
Protein production, purification, and 
crystallization. The TcpB120-250 protein was 
expressed using auto-induction media (24) and 
purified using nickel-affinity chromatography 
followed by size-exclusion chromatography. 
Peak fractions were pooled. SDS-PAGE analysis 
showed more than 95% protein purity. The 
protein was concentrated to 22 mg/ml and 
subjected to crystallization trials. The protein 
was crystallized in 0.1 M Bis-Tris pH 5.5, 0.2 M 
NaCl, and 25% w/v PEG3350 using the 
hanging-drop vapor diffusion method (25).   
Data collection and structure determination. 
Diffraction data were collected using the MX2 
beamline at the Australian Synchrotron, 
Melbourne, Australia, using the Blu-Ice software 
(26). Data indexing/integration and scaling were 
performed using XDS (27) and SCALA (28), 
respectively. The structure was solved by 
molecular replacement using Phaser (29), and 
the Paracoccus denitrificans TIR domain-
containing protein (PdTIR) structure (PDB ID 
3h16) (19) as a template model. PdTIR structure 
was the best model because of its high (61%) 
amino-acid-sequence identity with TcpB-TIR 
domain. Automated model building was 
performed using Autobuild within the Phenix 
package (30,31). Iterative model building in 
Coot (32) was carried out between rounds of 
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refinement in Phenix and Buster (30,33). 
Automatic non-crystallographic symmetry 
(autoNCS) with local structural similarity 
restraints (LSSR) was used throughout 
refinement in Buster (34). Structure validation 
was performed using MolProbity (35), and 
analyzed using Coot and PyMOL 
(http://www.pymol.org). Figures were prepared 
using PyMOL. The coordinates and structure 
factors have been deposited in the Protein Data 
Bank (PDB ID 4c7m). 
Multi-angle light scattering. Multi-angle light 
scattering coupled with size-exclusion 
chromatography (MALS) was performed using a 
DAWN HELEOS II 18-angle light scattering 
detector coupled with an Optilab rEX refractive 
index detector (Wyatt Technology, Santa 
Barbara, CA, USA) and combined inline with a 
pre-equilibrated Superdex 200 10/300 size-
exclusion column (GE Healthcare), using a 
buffer containing 50 mM Hepes pH 8.0, 250 
mM NaCl, and 1 mM DTT (36). All experiments 
were performed at room temperature and about 
300 µg of each sample was loaded. Molecular-
mass calculations were calculated at the top of 
the elution peaks using the Astra 6.1 software 
(Wyatt Technology, Santa Barbara, CA, USA) 
based on extrapolation from Debye plots (Zimm 
formalism) using a dn/dc value of 0.1850 ml g−1 
(37).  
Circular Dichroism (CD). CD spectra were 
measured using the Jasco J710 
spectropolarimeter (Tokyo, Japan), for TcpB-fl, 
TcpB120-250, TcpB1-119  and TcpB70-250 at 25°C. 
Samples were pre-dialyzed into 20 mM sodium 
phosphate pH 8.0, and 100 mM NaCl. Data were 
collected using 0.5 nm wavelength increments 
from 260 to 195 nm at 20 nm/min, with a 
spectral bandwidth of 1.0 nm, 0.1 mm path 
length cell, 0.5 sec response time, and five 
accumulations. 
Small-angle x-ray scattering (SAXS). Purified 
TcpB-fl, TcpB120-250, TcpB70-250 and TcpB1-119  
were gel-filtered using a buffer containing 50 
mM Hepes pH 8.0, 250 mM NaCl, and 1 mM 
DTT, at 4°C. Concentrations were obtained by 
UV absorbance at 280 nm. Data was collected at 
the SAXS/WAXS beamline of the Australian 
Synchrotron, Melbourne, Australia, on a Pilatus 
1M detector at a sample-to-detector distance of 
1.6 m. SAXS measurements were collected at 
20°C from dilution series made with post-peak 
gel-filtration buffer. 90 µL of sample was 
injected through a 1.5-mm-diameter quartz 
capillary at a rate of 1 µL/s, capturing images 
every 1 s. Consistent, successive exposures were 
normalized to transmitted intensity, reduced, 
scaled to absolute intensity using pure water, 
averaged and buffer-subtracted using 
ScatterBrain (http://www.synchrotron.org.au 
/index.php/aussyncbeamlines/saxswaxs/software
-saxswaxs). The ATSAS 2.5 software package 
was used for subsequent analyses (38-40). 
Guinier analysis was performed for q.Rg <1.3 
using AUTORG in PRIMUS, and data-sets were 
examined for concentration dependence and 
linearity. P(r) distributions were obtained for all 
constructs by indirect transformation in 
AUTOGNOM. Normalized Kratky plots were 
calculated as q.Rg vs. q.Rg.I(q)/I(0), and these 
were analyzed for increases at high-q indicative 
of flexibility. For constructs showing limited 
flexibility, molecular weights were estimated 
from the P(r) distributions using SAXSMoW 
(41), and those for highly flexible constructs 
were calculated from absolute I(0). Predicted 
scattering from the crystallographic dimer was 
calculated with CRYSOL (42) using default 
parameters. In cases where flexibility was 
limited and no concentration dependence was 
observed, ab inito models were generated from 
12 DAMMIF (43) runs under P2 symmetry 
restraints, and clustered and averaged in 
DAMAVER (44). 
 
RESULTS 
 
TcpB interacts with MAL, MyD88, and TLR4. 
We used co-immunoprecipitation (coIP) 
analyses to test in parallel the interaction of V5-
TcpB with HA-MAL, HA-MyD88, HA-TLR4, 
Flag-TRAM and Myc-IRAK-2 (all full-length 
proteins, with specific tags as indicated). We 
began by confirming known interactions 
between MAL and MyD88, MAL and TLR4, 
TRAM and MyD88 and TRAM and TLR4 
(Figure 1). V5-TcpB interacted specifically with 
HA-MAL, HA-MyD88 and HA-TLR4 (Figure 
2A-B), but not Flag-TRAM, Myc-IRAK-2 
(Figure 2C), or an HA-tagged control protein 
(Figure 2B). These results suggest that, in the 
case of TLR4 signaling, TcpB specifically 
targets the MAL/MyD88-dependent signaling, 
but not TRAM-dependent signaling. In previous 
studies, the TcpB BB-loop was suggested to be 
critical for function (10). To test this suggestion, 
we mutated the conserved glycine-158 to alanine 
in the BB-loop (V5-TcpBG158A), and tested the 
interaction with HA-MAL, HA-MyD88, and 
HA-TLR4. Critically, the G158A mutation 
Structure and function of Brucella TcpB TIR-domain	  
	   5	  
abolished the interaction with HA-TLR4 (Figure 
2B) and significantly reduced the interaction 
with HA-MAL (Figure 2A), but the interaction 
with HA-MyD88 was unaffected (Figure 2A), 
suggesting that only the interaction with MAL 
and TLR4 requires an intact TcpB BB-loop. 
 
TcpB disrupts the interaction between MAL and 
TLR4. Because TcpB can interact with TIR 
domains from multiple proteins, it seems likely 
that its mechanism of inhibition of TLR4 
signaling would involve disruption of 
receptor:adaptor or adaptor:adaptor TIR domain 
interactions. Therefore, we used competition 
assays to investigate the effects of TcpB on these 
interactions. To assess the effect of TcpB on 
MAL:MyD88, MAL:TLR4, TRAM:MyD88, or 
TRAM:TLR4 interactions, increasing amounts 
of recombinant full-length TcpB (TcpB-fl), the 
TcpB-TIR (TcpB120-250), or TcpB N-terminal 
domain (TcpB1-119), were incubated with the 
lysate of cells co-transfected with Flag-MAL 
and HA-MyD88, Flag-MAL and HA-TLR4, 
Flag-TRAM and HA-MyD88, or Flag-TRAM 
and HA-TLR4. The addition of increasing 
amounts of TcpB-fl, TcpB-TIR120-250 or TcpB1-
119  had no effect on the interaction between 
MAL and MyD88 (Figure 3A), TRAM and 
MyD88, and TRAM and TLR4 (Figure 3C-D). 
By contrast, under the same conditions, both 
TcpB-fl and TcpB-TIR120-250 abolished the 
interaction between MAL and TLR4 when the 
cell lysate was incubated with 10 µg or more of 
recombinant protein (Figure 3B). For the TcpB1-
119 titration, an interaction was still apparent at 
the highest concentration of recombinant protein 
(Figure 3B), suggesting that this region of TcpB 
does not impair the MAL:TLR4 interaction. 
Recombinant GST protein, used as a negative 
control, did not disrupt MAL:MyD88, 
TRAM:MyD88, MAL:TLR4 or the 
TRAM:TLR4 interactions (Figure 3A-D).  
 
The crystal structure of TcpB reveals unique 
loop conformations and surface features. To 
obtain structural insights into the TcpB-mediated 
suppression of TLR4 signaling, we determined 
the crystal structure of TcpB-TIR. Several 
constructs were expressed, purified, and 
subjected to crystallization trials (25). One of the 
constructs, encompassing residues 120-250 
(TcpB120-250), yielded plate-like crystals that 
diffracted x-rays to 2.6-Å resolution and the 
structure was refined to final Rwork/Rfree values of 
0.23/0.24. The small difference between 
Rwork/Rfree may reflect the usage of the local 
structure similarity restraints (LSSR) approach 
in autoNCS during refinement process (34). The 
crystals have the symmetry of the space group 
P21 with four molecules (A, B, C, and D) in the 
asymmetric unit (Table 1). Each of the 
molecules has a typical TIR-domain fold with a 
central five-stranded parallel β-sheet (βA-βE) 
surrounded by five α-helices (αA-αE) connected 
by loops (Figure 4A; the naming of secondary 
structure elements follows the nomenclature 
used for the structures of PdTIR and the TLR1 
TIR domain (13,19)). A portion of the αC helix 
of chain A (residues 188-189), the CD loop of 
chains B (199-204), C (199-203), and D (198-
204), and the BB-loop of chain C (156-160) 
have poor electron density and therefore could 
not be modeled. All of the four molecules have 
similar structures with an RMSD <0.65 Å for 
116 equivalent Cα atoms.  
A search using DALI (45) identified 
PdTIR (PDB ID 3h16) as the closest structural 
homologue with an RMSD value of 1.2 Å for 
127 Cα atoms and a Z score of 22.4. Mammalian 
TIR domain structures from MAL (PDB ID 
2y92; RMSD value of 2.5 Å for 104 Cα atoms 
and Z score of 10.4), MyD88 (PDB ID 4dom; 
RMSD value of 2.9 Å for 105 Cα atoms and Z 
score of 9.3), and TLR2 (PDB ID 1fyw; RMSD 
value of 2.8 Å for 109 Cα atoms and Z score of 
9.3) have less structural similarity. The structure 
reveals distinct loop conformations compared to 
other TIR domain structures (Figure 4B-E). 
Superposition of the structures of TcpB-TIR120-
250 and PdTIR reveals that the BB-loop adopts a 
similar conformation in both structures, while 
the conformations of the CD and DE loops are 
significantly different (Figure 4B). TcpB-TIR120-
250 also lacks the 310 helix between βB strand and 
αB helix observed in the PdTIR and MyD88 TIR 
domain structures (Figure 5) (18,19). In 
comparison to the mammalian TIR domain 
structures, TcpB adopts significantly different 
AB, BB, CD, DE, DD, and EE loop 
conformations (Figure 4C-E). Analysis of the 
surface electrostatic potential of TcpB120-250 
reveals that it contains extensive positively-
charged patches that are absent in the TIR 
domains of MAL or PdTIR, which both have 
strongly electronegative surfaces (Figure 6). It 
has been suggested that complementary-charged 
surfaces mediate TIR domain interactions 
(16,46). 
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TcpB exists as a dimer in solution. We examined 
the oligomeric state of recombinant TcpB 
constructs (TcpB-fl, TcpB120-250, and TcpB1-119) 
in solution by size-exclusion chromatography 
(SEC) coupled with multi-angle light scattering 
(MALS), and by small-angle x-ray scattering 
(SAXS). Full-length TcpB behaved as a stable 
dimer according to MALS, with an experimental 
molecular weight of 55.7 kDa, consistent with a 
theoretical dimer molecular weight of 56.0 kDa 
(Figure 7A). SAXS analysis of this protein was 
precluded by aggregation. Conversely, TcpB120-
250 was found to be in a dynamic equilibrium 
between a monomer and a dimer. Using MALS, 
the elution peak showed a molecular weight of 
23.7 kDa at the top of the peak (Figure 8A), 
between the expected weight of the dimeric 
(30.0 kDa) and monomeric (15.0 kDa) states. A 
decrease in molecular weight from 24.9-21.7 
kDa was observed across the peak, suggesting 
that the TcpB TIR domain is in a dynamic 
equilibrium between a monomer and a dimer 
(47). The SAXS-derived molecular weight was 
seen to increase from 24.6 kDa to 29.2 kDa 
across a dilution series, suggesting a 
concentration-dependent monomer-dimer 
equilibrium (Figure 9A-C). Similarly, TcpB1-119 
also displayed evidence of monomer-dimer 
equilibrium. The MALS elution peak showed a 
molecular weight of 17.5 kDa at the top of the 
peak, and the range of molecular weights 
observed across the peak corresponds to 19.1-
13.3 kDa. This is between the expected weight 
of the dimeric (26.0 kDa) and monomeric (13.0 
kDa) states (Figure 7B), while SAXS yielded a 
similarly intermediate molecular weight of 22.0 
± 0.2 kDa. Unlike TcpB120-250, TcpB1-119 did not 
show concentration dependence across the range 
studied by SAXS (Figure 9C). Using MALS, the 
SEC elution peak of TcpB70-250 showed a 
molecular weight of 34.1 kDa, close to a dimeric 
(41.0 kDa) state (Figure 7C), while the 
molecular weight based on SAXS was found to 
be 41.2 ± 0.2 kDa across a 4-fold dilution series, 
and no concentration-dependence was observed 
(Figure 9C). Guinier plots were linear (Figure 
9B) for the three constructs analysed. Overall, 
these results suggest that both the TIR and the 
N-terminal domains are necessary for TcpB to 
form a stable dimer. 
 
TIR:TIR domain interfaces in the TcpB crystals. 
The four molecules in the asymmetric unit of the 
TcpB120-250 crystals form two equivalent two-
fold symmetrical dimers (chains A:C and B:D), 
with total buried surface areas of 1266 Å and 
1283 Å, respectively (calculated using PISA 
(48)). The structural elements involved in these 
interfaces include the DD and EE-loops, and the 
αD and αE helices (Figure 10A). A network of 
hydrogen bonds and salt bridges stabilizes the 
interface (Figure 10B-C). Key interacting 
residues at the interface are conserved among a 
number of bacterial TIR domains (Figure 11A). 
At the core of the interface, the EE-loops are 
connected by hydrogen bonds between the 
hydroxyl oxygens from the side-chain of two 
S235 residues, and supported by the 
hydrophobic contacts between the two L236 
residues (Figure 10B). The S235 residues also 
form hydrogen bonds with the side-chain of 
N233, and the overall conformation of the EE-
loops is stabilized by the side-chain of the W211 
residues (Figure 10B). In the DD-loops, the two 
K213 residues form hydrogen bonds with each 
other and with the side-chains of E218 (αD 
helix) and E181 (αC helix) (Figure 10C). At the 
edge of the interface, the side-chain of D217 (αD 
helix) forms hydrogen bonds with the side-chain 
of R220 (αD helix) from the same chain and 
with the main-chain amide nitrogen of V239 (αE 
helix) from a neighboring chain (Figure 10C). 
The main-chain carbonyl oxygen of T234 (EE-
loop) also forms a hydrogen bond with the main-
chain nitrogen amide of Y216 (αD helix) from a 
neighboring chain (Figure 10C).  
 
Mutational analysis of the TcpB TIR domain 
dimer. To examine if the TcpB120-250 dimer 
interface observed in the crystals corresponds to 
the dynamic dimer observed in solution, we 
analyzed the effects of amino-acid substitutions 
in this interface on recombinant TcpB120-250 self-
association, using MALS. As the arrangement of 
molecules in the crystal structure suggests the 
BB-loop does not participate in dimerization, we 
mutated the conserved G158 residue to alanine 
as a negative control. The G158A mutation did 
not affect the TcpB120-250 dynamic equilibrium, 
yielding a molecular weight of 23.1 kDa (Table 
2 and Figure 8L). Out of eight residues in the 
crystal interface that were mutated, mutations of 
D217, Y216, K213, S235, L236, W211 and 
R220 substantially shifted the equilibrium 
towards monomeric state (Table 2 and Figure 
8B-F and 8H-K). Several of these residues, 
including Y216, K213, S235 and L236, occupy 
central positions in the crystal interface. The 
W211 and R220 residues are not directly 
involved in interactions between molecules, but 
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are important for maintaining the DD and EE-
loops, the αD helix, and the surrounding surface 
in the correct conformations. Mutation of N233 
only slightly affected the dimer equilibrium 
(Table 2 and Figure 8G).  
 
Mutations in the dimer interface reduce TcpB-
mediated inhibition of NF-κB activation. To test 
the functional relevance of the TcpB TIR-
domain dimerization, we analyzed the effect of 
the dimer interface mutants on NF-κB activation 
using LPS-responsive HEK293 cells stably 
expressing TLR4-MD2. In these experiments, 
we used only TcpB-fl, as we were unable to 
successfully express TcpB120-250 in HEK293 cells. 
As the BB-loop mutation (G158A) was shown to 
have an effect on TcpB function (10), this 
mutation was included in our experiment as a 
positive control. Whereas wild-type TcpB-fl 
effectively suppressed TLR4-mediated 
activation of an NF-κB reporter, the K213E, 
N233A, L236A and the R220A mutants all lost 
this inhibitory activity. As expected, the G158A 
mutant also showed a similar phenotype. By 
contrast, the D217A and Y216A mutants 
retained similar inhibitory activities to wild-type 
TcpB-fl (Figure 12). The K213A, S235A, 
W211A and the R220E mutants showed an 
intermediate phenotype between wild-type 
TcpB-fl and the G158A mutant (Figure 12).  
 
Structural characterization in solution confirms 
the dimer formation of TcpB TIR domain. We 
compared the SAXS data for TcpB120-250 to the 
dimeric molecule observed in the TcpB120-250 
crystal structure (Figure 9A). In spite of the 
concentration-dependence previously described, 
the theoretical scattering from the structure is 
relatively consistent. Some deviation in the 
<0.05 Å-1 and 0.1-0.2 Å-1 q-range is not 
unexpected in the presence of inter-particle 
effects. We therefore generated ab initio models 
for TcpB70-250 with P2 symmetry restraints 
(Figure 8D). Two clusters of reconstructions 
were observed, with incidences of 50% each 
from 12 DAMMIF (43) runs. Both clusters share 
a globular domain consistent with the size and 
shape of the crystal structure, and have extended 
features accounting for the C-terminal end of 
TcpB1-119. In one set of reconstructions, these 
features appear on both sides of the globular 
domain, while in others this occurs only on a 
single side (Figure 9D).  For TcpB1-119, a steady 
increase is observed at higher scattering angles 
in a normalized Kratky plot (Figure 9E); this 
behavior is consistent with a highly flexible and 
disordered peptide chain. Similar analysis for 
TcpB70-250 and TcpB120-250 indicates a lesser 
degree of flexibility (Figure 9E). Circular 
dichroism data for the TcpB1-119 showed a strong 
negative peak near 200 nm and a weaker peak 
near 220 nm, which suggests that TcpB1-119 
contains a mixture of α-helical and random-coil 
structure (Figure 9F). Modeling analyses using 
Phyre2 (49) suggest that both TcpB1-119 and the 
N-terminal domains of other similar bacterial 
TIR domain-containing proteins may form 
elongated anti-parallel or parallel α-helical 
coiled-coil structures.  
 
 
DISCUSSION 
 
TcpB interaction with MAL, MyD88 and TLR4. 
In this study, we used the Brucella melitensis 
TIR-domain-containing protein 
(TcpB/BtpA/Btp1) as a model system to shed 
light on the molecular mechanism of 
immunosuppression by bacterial TIR-domain-
containing proteins, using cell-based interaction 
studies and x-ray crystallography. TcpB belongs 
to a family of bacterial TIR-domain-containing 
proteins that includes proteins from Salmonella 
enterica serovar Enteritidis (TlpA), 
uropathogenic Escherichia coli (TcpC) and 
Staphylococcus aureus (11,50,51). Some of 
these proteins have been shown to suppress 
TLR4 and TLR2 signaling pathways (6). Several 
studies described their potential binding partners 
in the host. For example, TcpB and TcpC were 
shown to interact with MyD88 (7,11). Peptides 
corresponding to the BB and DD-loops of TcpC 
were shown to interact with TLR4 and MyD88, 
respectively (11,18). The TIR-domain-
containing protein from the non-pathogenic 
bacterium Paracoccus denitrificans (PdTLP) 
was shown to interact with MyD88 and TLR4 
(52). Using co-immunoprecipitation analyses, 
we found that TcpB interacts with MAL, 
MyD88 and TLR4 (Figure 2A-B), with the TcpB 
BB-loop being critical for interactions with 
MAL and TLR4 (Figure 2A-B). TcpB did not 
interact with TRAM and IRAK-2 (Figure 2C). 
Notably, it has been reported that MAL and 
MyD88 are both involved in TcpB-mediated 
inhibition of NF-κB activation (8,10). However, 
TcpB did not affect TLR9-mediated activation 
of NF-κB (a MyD88-dependent receptor) (8), 
but did antagonize TLR5 signaling (7). Recently, 
coIP studies identified an interaction between 
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TLR5 and MAL (53). Together with our coIP 
studies, it is therefore reasonable to suggest that 
TcpB also targets other MAL-mediated TLR 
signaling pathways.  
A recent report suggested that regions 
outside the TIR domain of MyD88 are involved 
in the interaction with TcpB, and that TcpB 
binding enforces an inactive state of MyD88 
(12). Our data suggest that the bacterial TIR-
domain-containing proteins may form 
complexes with multiple host proteins. A similar 
mechanism was reported for vaccinia virus 
A46R, which has been shown to target multiple 
host TIR-domain-containing proteins (54).  
Sengupta et al. (9) reported that TcpB 
interacts with MAL and does not interfere with 
the MAL:MyD88 interaction. We similarly 
observed that recombinant TcpB-fl, TcpB120-250 
and TcpB1-119 were unable to interfere with the 
MAL:MyD88 interaction (Figure 3A). Based on 
our observation that TcpB could interact with 
MAL and TLR4 at two opposite sides of the 
TcpB TIR domain dimer (see below), it is likely 
that TcpB rather interferes with the 
receptor:adaptor interactions. Increasing 
amounts of recombinant TcpB-fl or TcpB120-250 
proteins, but not TcpB1-119, interfered with the 
MAL:TLR4 interaction (Figure 3B). Our 
observations are thus consistent with the 
previously suggested mechanism of molecular 
mimicry, whereby TcpB mimics MAL function 
by binding to the plasma membrane using its N-
terminal domain, and competes with MAL for 
binding to TLR4 (Figure 13), rather than with 
MyD88 as suggested by Radhakrishnan et al. 
(10). 
TcpB dimerization. We demonstrate that the TIR 
domain from TcpB has a tendency to 
homodimerize, with the crystal structure and 
mutational studies suggesting that the DD and 
EE-loops, and the αD and αE helices are 
involved in the interface (Figure 10A). In this 
arrangement, the BB-loops from the two 
interacting molecules are exposed to the solvent 
for possible interaction with host molecules. 
Therefore, it is conceivable that MAL and TLR4 
could simultaneously interact with the TcpB TIR 
domain dimer, using the BB-loop-containing 
interfaces at the opposite sides of the dimer. It is 
unlikely that TcpB has a similar MyD88-binding 
interface to TcpC, because the TcpB TIR 
domain DD-loop participates in dimer formation. 
Notably, the DD-loops from the TIR domains of 
TcpB and TcpC share low sequence similarity 
(Figure 11A), possibly supporting different 
ffunctions. Importantly, the dimer interface we 
identified in the TcpB120-250 is also found in 
PdTIR crystals (19); to our knowledge, this is 
the first observation of a common interface 
shared between two different TIR domain 
structures, and suggests some parallels in the 
molecular basis of function among bacterial TIR 
domains. 
 Although in vivo studies have shown 
that a number of TIR-domain-containing 
proteins dimerize, the majority of isolated 
recombinant TIR domains have been reported to 
be monomers in solutions, and other regions in 
the molecules were found to be required for the 
proteins to form stable dimers (2,46,55). In 
solution, our study shows that isolated domains 
of TcpB are in reversible equilibrium between 
monomers and dimers, and both domains are 
required to form a stable TcpB dimer (Figure 7, 
8 and 9C). We confirmed, by mutational 
analysis of key interacting residues, that the 
dimer interface observed in the TcpB120-250 
crystals is responsible for TcpB120-250 
dimerization in solution (Table 3 and Figure 7). 
These analyses also show that the BB-loop does 
not participate in dimer formation, which further 
supports the suggested MAL and TLR4-binding 
interface. We further demonstrate, by using NF-
κB reporter assays, that a number of mutations in 
the dimer interface affected the ability of TcpB-
fl to inhibit NF-κB activation, although they did 
not necessarily disrupt dimerization completely 
(Figure 10). The apparent discordance for a 
small number of the mutations (e.g. Y216A, 
D217A) in affecting dimer formation versus 
reporter gene inhibition may reflect the 
necessary usage of truncated (MALS) versus 
full-length TcpB proteins (reporter assays) in the 
different assays.  
 Fekonja et al. (22) reported that bacterial 
TIR-domain-containing proteins use dimeric N-
terminal coiled-coil domains not only for 
membrane attachment, but also to enhance TIR 
domain dimer formation to aid in the inhibition 
of TLR signalling. Our data suggest that TcpB1-
119 by itself is highly flexible, with some limited 
α-helical character, and has a tendency to 
dimerize (Figure 9C-E and 7B). SAXS data 
further demonstrate the dimer formation of TcpB, 
with one of the two reconstructions suggesting 
that the N-terminal tails of the TIR domain could 
be on the opposite sides of the dimer (Figure 
9D), which would be consistent with the TcpB 
TIR domain dimer observed in the crystals 
(Figure 10A). Based on structural modeling, we 
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speculate that parts of TcpB1-119 could adopt an 
antiparallel or parallel coiled-coil structure. 
Future studies, will unveil the detailed structural 
characteristics of the N-terminal domains from 
bacterial TIR-domain-containing proteins. 
Conclusions. Understanding the molecular basis 
of the TIR-domain association between 
microbial and host TIR-domain-containing 
proteins has been a challenge, with the lack of 
structural information on heterotypic complexes 
making it difficult to model a coherent 
mechanism of action. Our study has provided 
significant insights into the mechanism of TcpB 
interaction with host signaling molecules, at 
both molecular and structural levels. We find 
that TcpB dimerization is important for function. 
We believe that the dimer interface reported in 
this study and the involvement of the BB-loop in 
the interaction of TcpB with host molecules 
could be used as targets for developing peptides 
as anti-inflammatory agents. Ultimately, such an 
approach could lead to the development of novel 
therapeutics for the treatment of chronic 
inflammatory diseases.  
While our manuscript was in preparation, 
Kaplan-Turkoz et al. published the 3.15-Å 
resolution crystal structure of the TIR domain of 
TcpB (56). The structure shows the analogous 
dimeric arrangement we see in our crystals. 
Mutagenesis of the interface residues in the 
context of full-length protein similarly supports 
our suggestions of the dimerization interface (for 
example. the S235A mutation). Because the 
crystallized protein contained some additional 
N-terminal residues (starting at residue 75), the 
authors find that the N-terminal region of one 
monomer packs against the dimer. This feature 
is consistent with the conclusions of our 
biophysical experiments. Comparison of this 
dimeric structure to the SAXS data for Tcp70-250 
yielded poor fits both prior to and after modeling 
of missing residues (analysis not shown).  It 
appears that structural information on extended 
constructs will be required to understand the 
structural basis of the role of the N-terminal 
domain of TcpB in its dimerization.
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FIGURE LEGENDS 
 
FIGURE 1 Co-immunoprecipitation of TcpB with MAL, MyD88, and TLR4. HEK293 cells (1 x 106 
cells/well) were co-transfected, using lipofectamine 2000, with 1 µg of V5-TcpB or V5-TcpBG158A 
and 1 µg of: A. HA-MAL (lane 6-7), HA-MyD88 (lane 8-9); B. HA-TLR4 (lane 5-6), an HA-tagged 
control protein (lane 7-8); and C. Flag-TRAM (lane 7-8), or Myc-IRAK-2 (lane 9-10). After 24 h, the 
lysates were immunoprecipitated with anti-V5 bound to pre-washed Dynabeads® Protein G (Life 
Technologies) magnetic beads, followed by a 2-h incubation at 4°C with rotation. Beads were then 
subjected to washing, SDS-PAGE and immunoblotting with the indicated antibodies. Data in A, B, 
and C were generated in the same experiment, and both panels are representative of two independent 
experiments.  
 
FIGURE 2 Western-blot analysis of the controls for the co-immunoprecipitation analysis. Using 
lipofectamine 2000, HEK293 cells (1 x 106 cells/well) were co-transfected with: A. 1 µg Flag-MAL 
and 1 µg HA-MyD88 (lane 4) or 1 µg Myc-IRAK-2 (lane 5), and 1 µg Flag-TRAM and 1 µg HA-
MyD88 (lane 9) or 1 µg Myc-IRAK-2 (lane 10); and B. 1 µg Flag-MAL and 1 µg HA-TLR4 (lane4) 
or HA-tagged control (lane 5), and 1 µg Flag-TRAM and 1 µg HA-TLR4 (lane 9) or HA-tagged 
control (lane 10). The lysates were immunoprecipitated with anti-Flag-M2 antibody bound to pre-
washed Dynabeads® Protein G (Life Technologies) magnetic beads, followed by a 2 h incubation at 
4°C, with rotation. Beads were then subjected to washing, SDS-PAGE, and immunoblotting with the 
indicated antibodies. Data in A and B were generated in the same experiment, and both panels are 
representative of two independent experiments. Notably, MAL:IRAK-2 and TRAM:MyD88 
interactions have been reported previously (57-59). 
 
FIGURE 3 The effect of recombinant TcpB on the interaction between MAL:MyD88, MAL:TLR4, 
TRAM:MyD88 and TRAM:TLR4. HEK293 cells (1 x 106 cells/well) were co-transfected, using 
lipofectamine 2000, with 1 µg Flag-MAL with: A. 1 µg HA-MyD88; or B. 1 µg HA-TLR4, and 1 µg 
Flag-TRAM; with C. 1 µg HA-MyD88; or D. 1 µg HA-TLR4. After 24 h of transfection, the lysates 
were immunoprecipitated with anti-Flag-M2 bound to pre-washed Dynabeads® Protein G (Life 
Technologies) magnetic beads, followed by a 2-h incubation at 4°C, with rotation. Increasing amounts 
(1, 10, 100 µg) of recombinant TcpB-fl (A-D, lanes 2-4), TcpB120-250 (A-D, lanes 5-7), TcpB1-119 (A-D, 
lanes 9-11) or GST (A-D, lanes 12-14) were added and incubated for 3 hours at 4°C, with rotation. 
Beads were then subjected to washing, SDS-PAGE, and immunoblotting with the indicated antibodies. 
Data are representative of two independent experiments.  
 
FIGURE 4 Crystal structure of the TcpB TIR domain and comparison with available TIR-domain 
structures. A. Cartoon representation of the TcpB120-250 crystal structure, colored by secondary 
structure elements (α-helices, blue; β-sheet, purple; loop regions, pink). B-E. Ribbon representation of 
the superposition of TcpB120-250 (cyan) (this study), with: B. PdTIR (orange) (PDB ID 3h16); and the 
TIR domains from: C. TLR2 (blue) (PDB ID 1fyw); D. MyD88 (green) (PDB ID 4dom); and E. MAL 
(yellow) (PDB ID 2y92). 
 
FIGURE 5 Superposition of TIR domains to highlight the differences in 310 helices. Superposition of 
the structure of TcpB120-250 (cyan), PdTIR (orange), and the TIR domain of MyD88 (green). The 310 
helices are colored red and this structural feature is only found in the structures of PdTIR and the 
MyD88 TIR domain and is missing from the TcpB-TIR120-250 structure. 
 
FIGURE 6 Comparison of electrostatic properties. The solvent-accessible surfaces of: A. TcpB120-250; 
B. PdTIR; C. TLR4 TIR domain; D. MyD88 TIR domain; and E. MAL TIR domain, are colored 
according to electrostatic potential, ranging from blue (positive charge) through white to red (negative 
charge) in the range ± 0.5 kT/e. The electrostatic potential was calculated using the APBS tool within 
the Pymol software (60). The upper panel is a cartoon representation of the TcpB120-250 structure in 
panel A, to help with the orientation of the structures. The TLR4 TIR domain structure was modeled 
using Phyre2 (49). TcpB120-250 has a distinctive positive charge across an area covering the βB, BB-
loop and αB, compared to scattered negatively-charged patches in PdTIR. The TIR domains from the 
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mammalian proteins MyD88, MAL and TLR4 are characterized by extensive positively or negatively 
charged patches across distant regions. 
 
FIGURE 7 MALS analyses of TcpB-fl, TcpB1-119, and TcpB70-250. The traces show protein 
concentration (arbitrary units; blue lines) and the molecular-weight distribution across the peaks (red 
lines), for A. TcpB-fl; B. TcpB1-119; and C. TcpB70-250. About 300 µg of each protein was used in a 
buffer containing 50 mM Hepes pH 8.0, 250 mM NaCl, and 1 mM DTT. 
 
FIGURE 8 MALS analyses of wild-type and mutant TcpB120-250. The traces show protein 
concentration (arbitrary units; blue lines) and the molecular weight distribution across the peaks (red 
lines), for A. wild-type TcpB120-250; and the B. D217A; C. Y216A; D. K213A; E; K213E, F; S235A, 
G; N233A, H; L236A, I; W211A, J; R220A, K; R220E, L; G158A mutants. About 300 µg of each 
purified protein was used in a buffer containing 50 mM Hepes pH 8.0, 250 mM NaCl, and 1 mM DTT.  
 
FIGURE 9 Small-angle x-ray scattering (SAXS) data. A. Experimental scattering from the TcpB70-250 
and TcpB120-250 proteins is plotted in black, with 1σ error bars shown in gray, as I(q) versus q on an 
arbitrary, logarithmic scale. The fits of representative models from the two clusters of ab initio 
reconstructions are shown in purple on the TcpB70-250 curve, and calculated scattering from the 
crystallographic dimer is shown in cyan, fitting TcpB120-250 to a χ value of 5.8. B. Highest-
concentration datasets for all three constructs, transformed as ln I(q) vs. q2, demonstrating linearity 
over the ranges where q.Rg < 1.3. C. Molecular weights are plotted for TcpB120-250, TcpB70-250, and 
TcpB1-119. Dotted lines indicate predicted molecular weights of dimeric and monomeric species where 
noted, and are colored by construct. D. Representative (inner) and averaged (outer) ab initio models 
are shown in purple for the two clusters restored from TcpB70-250 modeling, as surface representation 
with van der Waals radii at 3 Å. The dimeric crystal structure in cartoon representation (cyan) is 
manually superimposed onto the globular domain. E. Normalized, dimensionless Kratky plots are 
shown for the three constructs of TcpB, and for a stable, globular standard, glucose isomerase. 
Increases at higher scattering angle indicating flexibility are observed in all constructs, with TcpB1-119 
showing the most disorder. F. UV CD spectra (195 to 260 nm) of TcpB-fl (green), TcpB70-250 (purple), 
TcpB120-250 (cyan), and TcpB1-119 (red). 
 
FIGURE 10 The TcpB TIR:TIR domain interface observed in the crystal structure. A. Cartoon 
representation of the dimer interface. The interface involves the DD and EE-loops, and the αD and αE 
helices. B. A detailed overview of the dimer interface. The side chains of key residues involved in 
close contacts are displayed in wire-frame representation. A 40% transparency has been applied to the 
dimer ribbon diagram. 
 
FIGURE 11 Multiple sequence alignment of TIR domains. The amino acid sequences of TcpB-TIR 
(residues 119-250) and A. PdTIR (residues 167-299), and the TIR domains from the uropathogenic 
Escherichia coli TIR-domain-containing protein (TcpC-TIR) (residues 171-307), the Salmonella 
enterica serovar Enteritidis TIR-domain-containing protein (TlpA-TIR) (residues 160-293), and 
Staphylococcus aureus TIR-domain-containing protein (Sa-TIR) (residues 143-280); and B. the TIR 
domain from MAL (residues 86-256), MyD88 (residues 161-296), TLR4 (residues 587-752), TLR2 
(residues 641-784), TLR1 (637-786), and TLR10 (residues 634-811), were aligned using MUSCLE 
(61). The alignment was formatted using ESPript (62). The positions of secondary structure elements 
of TcpB-TIR are shown above the alignment. Conserved residues are shown in white on red 
background. Similar residues are shown in red and surrounded by red boxes. Key residues in TcpB-
TIR dimer contact are shown in blue. 
 
FFIGURE 12 The dimer interface is important for TcpB function. HEK293-TLR4-MD2 cells (8 x 
104 cells/well) were co-transfected for 24 h with 200 ng of plasmids encoding V5-TcpB (wild type), 
V5-TcpB mutants (D217A, Y216A, K213A, K213E, S235A, N233A, L236A, W211A, R220A, 
R220E and G158A) or empty vector pGL-2B (EV) with NF-κB luciferase reporter gene (100 ng), and 
phRL-TK reporter gene (20 ng) using lipofectamine 2000. The final amount of DNA (460 ng) was 
kept constant in all transfections by adding empty vector (EV) pGL-2B. Cells were stimulated with 
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100 ng/ml LPS for 8 h, and lysed with the Promega Lysis buffer. Data (average of n = 3) are 
displayed as luciferase activity, relative to Renilla luciferase activity. Error bars represent SEM of 
three independent experiments. ****, p < 0.0001 compared to EV plus LPS.   
 
Figure 13 Schematic modeling of the TcpB inhibition of TLR4 signaling. Oval shapes represent 
TcpB (orange), TLR4 (blue), MAL (yellow), and MyD88 (green). The model emphasizes the key 
findings from our study and is a simplified diagram of the signalling system. For example, the exact 
domains involved in the interactions between these proteins have not yet been clearly defined, and 
thus the model does not show specific domain interactions. A. A simplified representation of the 
TLR4 signaling pathway, showing the activation and dimerization of TLR4 creates a platform to form 
a complex with MAL and MyD88. B. The presence of TcpB causes suppression of the TLR4 
signaling pathway, by forming a complex with TLR4, MAL, and MyD88. 
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Table 1 Crystallographic data 
Diffraction data statistics  
 Space group      P21 
 Unit cell dimensions (Å)    a = 51.97 
        b = 73.68 
        c = 74.76 
        β = 93.29° 
 Molecules per asymmetric unit    4 
 Resolution range (Å)     52.43- 2.71 (2.57-2.71)a 
 No. of unique observations    18090 
 Completeness (%)     100.0 (99.7) 
 Multiplicity       3.7 (3.7) 
 Rmerge (%)b      8.9 (79.0) 
 Average I/σ(I) (%)     10.6 (1.9) 
Refinement statistics  
 Resolution (Å)      42.42-2.57 
 No. of reflections, work set    17070  
 No. of reflections, test set    1009 
 Rwork (%)c      23.17 
 Rfree (%)d      24.01 
 No. of protein atoms     4061 
 No. of water molecules      8 
 Overall B factor (Å2)     59.46 
 R.m.s. deviations from ideal values  
  Bonds (Å)     0.010 
  Angles (o)     1.05 
 Ramachandran plot (%)e  
  Favored     98.98 
  Disallowed     0 
a  Numbers in parenthesis are for the highest resolution shell. 
b Rmerge = ∑hkl(∑i(|I hkl,i-<I hkl >|))/∑hkl,i <I hkl>, where I hkl,i is the intensity of an individual measurement 
of the reflection with Miller indices h, k and l, and <Ihkl> is the mean intensity of that reflection.  
c Rwork = ∑hkl(||Fobshkl|-|Fcalchkl||)/|Fobshkl|, where |Fobshkl| and |Fcalchkl| are the observed and calculated 
structure factor amplitudes. 
d Rfree is equivalent to Rwork but calculated with reflections (5.6%) omitted from the refinement process. 
e Calculated using MolProbity (35). 
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Table 2 MALS analysis of the TcpB TIR-domain mutations in the dimer interface  
 
Protein variant Location in the crystal 
structure 
Experimental molecular 
weight (kDa) * 
Wild-type TcpB120-250 - 23.7 ± 0.05 
(24.9 - 21.7) 
D217A αD helix 18.5 ± 0.04 
(21.1 - 16.1) 
Y216A αD helix 19.6 ± 0.08 
(21.7 - 17.0) 
K213A DD loop 17.5 ± 0.08 
(20.1 - 16.0) 
K213E DD loop 18.4 ± 0.07 
(21.6 - 16.4) 
S235A EE loop 19.4 ± 0.06 
(19.9 - 17.4) 
N233A EE loop 21.5 ± 0.05 
(24.7 - 19.9) 
L236A EE loop 18.9 ± 0.05 
(20.0 - 16.4) 
W211A DD loop 18.1 ± 0.04 
(19.9 - 16.5) 
R220A αD helix 18.6 ± 0.06 
(22.3 - 16.8) 
R220E αD helix 19.4 ± 0.08 
(21.0 - 17.8) 
G158A BB loop 23.1 ± 0.06 
(24.4 - 20.0)  
 
* The theoretical molecular weight of the wild-type TcpB120-250 monomer is 15.0 kDa. The position of 
the mutations in the dimer interface and the experimental molecular weights at the top of the elution 
peak of the mutants obtained from MALS are presented. Errors are calculated by Astra software and 
relate to the uncertainty in the molecular weight calculation. The values in parentheses correspond to 
the range in the calculated molecular weight across the peak (Figure 8)  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
 
 
  
Structure and function of Brucella TcpB TIR-domain	  
	   25	  
Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
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Figure 10 
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Figure 11 
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Figure 12 
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Figure 13 
 
 
 
